---
document_datetime: 2026-01-06 17:25:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kapruvia.html
document_name: kapruvia.html
version: success
processing_time: 0.1185978
conversion_datetime: 2026-01-10 11:11:29.970309
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kapruvia

[RSS](/en/individual-human-medicine.xml/67556)

##### Authorised

This medicine is authorised for use in the European Union

difelikefalin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kapruvia](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kapruvia is a medicine used to treat moderate to severe pruritus (itching) in adults with chronic kidney disease who are on haemodialysis (treatment with a machine that filters toxins from the blood).

Kapruvia contains the active substance difelikefalin.

Expand section

Collapse section

## How is Kapruvia used?

Kapruvia can only be obtained with a prescription and treatment should be given by a healthcare professional with relevant experience. The medicine is given as an injection into the vein at the end of a haemodialysis procedure. It is given three times per week and the dose depends on the patient's weight.

For more information about using Kapruvia, see the package leaflet or contact your doctor or pharmacist.

## How does Kapruvia work?

Difelikefalin, the active substance in Kapruvia, is an opioid that bind to receptors (targets) on nerves and immune cells involved in controlling itching and inflammation. By binding to the receptors (called kappa opioid receptors), difelikefalin activates them, reducing inflammation that could lead to itchiness and decreasing the signals that lead to the feeling of itchiness itself.

## What benefits of Kapruvia have been shown in studies?

Kapruvia was effective at reducing the severity of pruritus in two main studies involving adults experiencing moderate to severe itchiness associated with chronic kidney disease. The main measure of effectiveness was a self-reported reduction of the worst level of itchiness experienced in a day.

The first study involved 378 adults with chronic kidney disease who had been on haemodialysis for at least three months. Of the patients taking Kapruvia, 51% reported a reduction of at least three points on the itchiness scale, compared with 28% who were taking a placebo (dummy treatment).

In the second study, involving 473 adults with chronic kidney disease who had been on haemodialysis for at least three months, 54% of the patients taking Kapruvia reported an improvement of at least three points on the itchiness scale, compared to 42% of the 236 taking a placebo.

## What are the risks associated with Kapruvia?

The most common side effects with Kapruvia (which may affect up to 1 in 10 people) are sleepiness and paraesthesia (sensations like numbness, tingling, pins and needles). Less common side effects (which may affect up to 1 in 100 people) are dizziness, headache, nausea (feeling sick), vomiting, diarrhoea and mental status changes (such as feeling confused). Most of these side effects were mild or moderate.

For the full list of side effects of Kapruvia, see the package leaflet.

## Why is Kapruvia authorised in the EU?

In the clinical trials, Kapruvia was shown to be effective at reducing the feeling of itchiness experienced by patients as a result of their lack of functioning kidneys. In addition, the side effects are considered manageable. Therefore, the European Medicines Agency decided that Kapruvia's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kapruvia?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kapruvia have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kapruvia are continuously monitored. Side effects reported with Kapruvia are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kapruvia

Kapruvia received a marketing authorisation valid throughout the EU on 25 April 2022.

Kapruvia : EPAR - Medicine Overview

Reference Number: EMA/205469/2022

English (EN) (121.54 KB - PDF)

**First published:** 28/04/2022

[View](/en/documents/overview/kapruvia-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-829)

български (BG) (142.88 KB - PDF)

**First published:**

28/04/2022

[View](/bg/documents/overview/kapruvia-epar-medicine-overview_bg.pdf)

español (ES) (120.38 KB - PDF)

**First published:**

28/04/2022

[View](/es/documents/overview/kapruvia-epar-medicine-overview_es.pdf)

čeština (CS) (142.3 KB - PDF)

**First published:**

28/04/2022

[View](/cs/documents/overview/kapruvia-epar-medicine-overview_cs.pdf)

dansk (DA) (119.59 KB - PDF)

**First published:**

28/04/2022

[View](/da/documents/overview/kapruvia-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.51 KB - PDF)

**First published:**

28/04/2022

[View](/de/documents/overview/kapruvia-epar-medicine-overview_de.pdf)

eesti keel (ET) (120.35 KB - PDF)

**First published:**

28/04/2022

[View](/et/documents/overview/kapruvia-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.44 KB - PDF)

**First published:**

28/04/2022

[View](/el/documents/overview/kapruvia-epar-medicine-overview_el.pdf)

français (FR) (121.8 KB - PDF)

**First published:**

28/04/2022

[View](/fr/documents/overview/kapruvia-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.13 KB - PDF)

**First published:**

28/04/2022

[View](/hr/documents/overview/kapruvia-epar-medicine-overview_hr.pdf)

italiano (IT) (119.06 KB - PDF)

**First published:**

28/04/2022

[View](/it/documents/overview/kapruvia-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.88 KB - PDF)

**First published:**

28/04/2022

[View](/lv/documents/overview/kapruvia-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.6 KB - PDF)

**First published:**

28/04/2022

[View](/lt/documents/overview/kapruvia-epar-medicine-overview_lt.pdf)

magyar (HU) (140.81 KB - PDF)

**First published:**

28/04/2022

[View](/hu/documents/overview/kapruvia-epar-medicine-overview_hu.pdf)

Malti (MT) (143.76 KB - PDF)

**First published:**

28/04/2022

[View](/mt/documents/overview/kapruvia-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.47 KB - PDF)

**First published:**

28/04/2022

[View](/nl/documents/overview/kapruvia-epar-medicine-overview_nl.pdf)

polski (PL) (143.88 KB - PDF)

**First published:**

28/04/2022

[View](/pl/documents/overview/kapruvia-epar-medicine-overview_pl.pdf)

português (PT) (121.24 KB - PDF)

**First published:**

28/04/2022

[View](/pt/documents/overview/kapruvia-epar-medicine-overview_pt.pdf)

română (RO) (139.2 KB - PDF)

**First published:**

28/04/2022

[View](/ro/documents/overview/kapruvia-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.35 KB - PDF)

**First published:**

28/04/2022

[View](/sk/documents/overview/kapruvia-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.11 KB - PDF)

**First published:**

28/04/2022

[View](/sl/documents/overview/kapruvia-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.87 KB - PDF)

**First published:**

28/04/2022

[View](/fi/documents/overview/kapruvia-epar-medicine-overview_fi.pdf)

svenska (SV) (119.06 KB - PDF)

**First published:**

28/04/2022

[View](/sv/documents/overview/kapruvia-epar-medicine-overview_sv.pdf)

Kapruvia : EPAR - Risk management plan summary

English (EN) (141.47 KB - PDF)

**First published:** 28/04/2022

[View](/en/documents/rmp-summary/kapruvia-epar-risk-management-plan-summary_en.pdf)

## Product information

Kapruvia : EPAR - Product Information

English (EN) (278.56 KB - PDF)

**First published:** 28/04/2022

**Last updated:** 06/01/2026

[View](/en/documents/product-information/kapruvia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-577)

български (BG) (304.65 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/bg/documents/product-information/kapruvia-epar-product-information_bg.pdf)

español (ES) (225.66 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/es/documents/product-information/kapruvia-epar-product-information_es.pdf)

čeština (CS) (291.49 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/cs/documents/product-information/kapruvia-epar-product-information_cs.pdf)

dansk (DA) (182.25 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/da/documents/product-information/kapruvia-epar-product-information_da.pdf)

Deutsch (DE) (214.31 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/de/documents/product-information/kapruvia-epar-product-information_de.pdf)

eesti keel (ET) (178.67 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/et/documents/product-information/kapruvia-epar-product-information_et.pdf)

ελληνικά (EL) (328.7 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/el/documents/product-information/kapruvia-epar-product-information_el.pdf)

français (FR) (183.11 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/fr/documents/product-information/kapruvia-epar-product-information_fr.pdf)

hrvatski (HR) (279.68 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/hr/documents/product-information/kapruvia-epar-product-information_hr.pdf)

íslenska (IS) (186.4 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/is/documents/product-information/kapruvia-epar-product-information_is.pdf)

italiano (IT) (187.84 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/it/documents/product-information/kapruvia-epar-product-information_it.pdf)

latviešu valoda (LV) (296.5 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/lv/documents/product-information/kapruvia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (313.5 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/lt/documents/product-information/kapruvia-epar-product-information_lt.pdf)

magyar (HU) (268.75 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/hu/documents/product-information/kapruvia-epar-product-information_hu.pdf)

Malti (MT) (292.48 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/mt/documents/product-information/kapruvia-epar-product-information_mt.pdf)

Nederlands (NL) (185.2 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/nl/documents/product-information/kapruvia-epar-product-information_nl.pdf)

norsk (NO) (181.46 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/no/documents/product-information/kapruvia-epar-product-information_no.pdf)

polski (PL) (299.29 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/pl/documents/product-information/kapruvia-epar-product-information_pl.pdf)

português (PT) (223.63 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/pt/documents/product-information/kapruvia-epar-product-information_pt.pdf)

română (RO) (293.36 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/ro/documents/product-information/kapruvia-epar-product-information_ro.pdf)

slovenčina (SK) (320.36 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/sk/documents/product-information/kapruvia-epar-product-information_sk.pdf)

slovenščina (SL) (314.06 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/sl/documents/product-information/kapruvia-epar-product-information_sl.pdf)

Suomi (FI) (182.85 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/fi/documents/product-information/kapruvia-epar-product-information_fi.pdf)

svenska (SV) (217.17 KB - PDF)

**First published:**

28/04/2022

**Last updated:**

06/01/2026

[View](/sv/documents/product-information/kapruvia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000316043 06/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kapruvia : EPAR - All authorised presentations

English (EN) (76.2 KB - PDF)

**First published:** 28/04/2022

[View](/en/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-906)

български (BG) (63.94 KB - PDF)

**First published:**

28/04/2022

[View](/bg/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.27 KB - PDF)

**First published:**

28/04/2022

[View](/es/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (80.76 KB - PDF)

**First published:**

28/04/2022

[View](/cs/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.57 KB - PDF)

**First published:**

28/04/2022

[View](/da/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (78.82 KB - PDF)

**First published:**

28/04/2022

[View](/de/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.71 KB - PDF)

**First published:**

28/04/2022

[View](/et/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (80.13 KB - PDF)

**First published:**

28/04/2022

[View](/el/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_el.pdf)

français (FR) (77.53 KB - PDF)

**First published:**

28/04/2022

[View](/fr/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.11 KB - PDF)

**First published:**

28/04/2022

[View](/hr/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (80.93 KB - PDF)

**First published:**

28/04/2022

[View](/is/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (75.82 KB - PDF)

**First published:**

28/04/2022

[View](/it/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.92 KB - PDF)

**First published:**

28/04/2022

[View](/lv/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (80.69 KB - PDF)

**First published:**

28/04/2022

[View](/lt/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.15 KB - PDF)

**First published:**

28/04/2022

[View](/hu/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.93 KB - PDF)

**First published:**

28/04/2022

[View](/mt/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (75.75 KB - PDF)

**First published:**

28/04/2022

[View](/nl/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (76.95 KB - PDF)

**First published:**

28/04/2022

[View](/no/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_no.pdf)

polski (PL) (80.87 KB - PDF)

**First published:**

28/04/2022

[View](/pl/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_pl.pdf)

português (PT) (77.33 KB - PDF)

**First published:**

28/04/2022

[View](/pt/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_pt.pdf)

română (RO) (79.16 KB - PDF)

**First published:**

28/04/2022

[View](/ro/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (82.18 KB - PDF)

**First published:**

28/04/2022

[View](/sk/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.4 KB - PDF)

**First published:**

28/04/2022

[View](/sl/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.54 KB - PDF)

**First published:**

28/04/2022

[View](/fi/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.84 KB - PDF)

**First published:**

28/04/2022

[View](/sv/documents/all-authorised-presentations/kapruvia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kapruvia Active substance difelikefalin International non-proprietary name (INN) or common name difelikefalin Therapeutic area (MeSH) Pruritus Anatomical therapeutic chemical (ATC) code V03AX

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005612

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Vifor Fresenius Medical Care Renal Pharma France

100-101 Terrasse Boieldieu

Opinion adopted 24/02/2022 Marketing authorisation issued 25/04/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kapruvia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.22 KB - PDF)

**First published:** 06/01/2026

[View](/en/documents/procedural-steps-after/kapruvia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kapruvia : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (106.99 KB - PDF)

**First published:** 25/07/2022

**Last updated:** 06/01/2026

[View](/en/documents/procedural-steps-after/kapruvia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kapruvia : EPAR - Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006

Reference Number: EMA/224087/2024

English (EN) (856.83 KB - PDF)

**First published:** 30/05/2024

[View](/en/documents/variation-report/kapruvia-epar-assessment-report-paediatric-studies-submitted-according-article-46-regulation-ec-no-1901-2006_en.pdf)

## Initial marketing authorisation documents

Kapruvia : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/152430/2022

English (EN) (3.33 MB - PDF)

**First published:** 28/04/2022

[View](/en/documents/assessment-report/kapruvia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Kapruvia

Adopted

Reference Number: EMA/CHMP/107869/2022

English (EN) (126.01 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kapruvia_en.pdf)

#### News on Kapruvia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

**This page was last updated on** 06/01/2026

## Share this page

[Back to top](#main-content)